Neboglamin
 | |
| IUPAC ime | |
|---|---|
(4S)-4-Amino-5-[(4,4-dimethilcikloheksil)amino]-5-oksopentanoinska kiselina | |
| Identifikatori | |
| CAS broj | 163000-63-3 |
| ATC kod | None |
| PubChem | CID 3074827 |
| ChemSpider | 2333649 |
| UNII | 12EA34U5B8  |
| Sinonimi | Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine |
| Hemijski podaci | |
| Formula | C13H24N2O3 |
| Molarna masa | 256,35 g·mol−1 |
| |
| |
Neboglamine (INN) (razvojno kodno ime CR-2249, XY-2401), ranije poznat kao nebostinel, je pozitivni alosterični modulator glicinskog mesta NMDA receptora koji se istražuje firma Rottapharm za lečenje šizofrenije i zavisnosti od kokaina.[1][2][3][4][5][6] On pokazuje efekte poboljšanja kognicije i pamćenja na životinjskim modelima.[7][8][9] Prema podacima iz juna 2015. ovaj materijal je u fazi II kliničkih ispitivanja za šizofreniju i zloupotrebu kokaina.[10]
Reference
[уреди | уреди извор]- ^ Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M (мај 2010). „Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat”. Pharmacological Research. 61 (5): 430—6. PMID 20045056. doi:10.1016/j.phrs.2009.12.010.
- ^ Kantrowitz J, Javitt DC (март 2012). „Glutamatergic transmission in schizophrenia: from basic research to clinical practice”. Current Opinion in Psychiatry. 25 (2): 96—102. PMC 5224527
. PMID 22297716. doi:10.1097/YCO.0b013e32835035b2.
- ^ „Drug Development in Schizophrenia: Summary and Table”. Pharmaceutical Medicine. 28 (5): 265—271. 2014. ISSN 1178-2595. S2CID 8513976. doi:10.1007/s40290-014-0070-6.
- ^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (новембар 2012). „Novel NMDA receptor modulators: an update”. Expert Opinion on Therapeutic Patents. 22 (11): 1337—52. PMC 3677696 . PMID 23009122. doi:10.1517/13543776.2012.728587.
- ^ Zink M, Correll CU (мај 2015). „Glutamatergic agents for schizophrenia: current evidence and perspectives”. Expert Review of Clinical Pharmacology. 8 (3): 335—52. PMID 25916667. S2CID 39547774. doi:10.1586/17512433.2015.1040393.
- ^ Köster LS, Carbon M, Correll CU (децембар 2014). „Emerging drugs for schizophrenia: an update”. Expert Opinion on Emerging Drugs. 19 (4): 511—31. PMID 25234340. S2CID 42729570. doi:10.1517/14728214.2014.958148.
- ^ Garofalo P, Colombo S, Lanza M, Revel L, Makovec F (децембар 1996). „CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice”. The Journal of Pharmacy and Pharmacology. 48 (12): 1290—7. PMID 9004193. S2CID 34902435. doi:10.1111/j.2042-7158.1996.tb03938.x .
- ^ Lanza M, Bonnafous C, Colombo S, Revel L, Makovec F (август 1997). „Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex”. Neuropharmacology. 36 (8): 1057—64. PMID 9294970. S2CID 11958361. doi:10.1016/S0028-3908(97)00092-0.
- ^ Lanza M, Makovec F (1997). „Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator”. CNS Drug Reviews. 3 (3): 245—259. ISSN 1080-563X. doi:10.1111/j.1527-3458.1997.tb00326.x.
- ^ „Neboglamine”. AdisInsight. Приступљено 2015-06-10.
